# US 11,110,105 B2 · Compounds, composition and uses thereof for treating cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,110,105 B2 - Document ID: US11110105B2 - Status: Granted - Kind: B2 - Application number: 16/604,599 - Filed: 2018-04-11 - Published: 2020-09-24 - Granted: 2021-09-07 - Earliest claimed: 2017-04-12 - Assignees: Institut Gustave Roussy - Applicants: Institut Gustave Roussy - Inventors: Sébastien Apcher; Alison Pierson; Mathilde Boulpicante; Zafiarisoa Dolor Renko; Mouad Alami; Romain Darrigrand - Web page: https://patentgrep.com/patent/US11110105B2 ## CPC - A61K 31/665: having oxygen as a ring hetero atom, e.g. fosfomycin - C07D 311/30: not hydrogenated in the hetero ring, e.g. flavones - A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)} - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 35/00: Antineoplastic agents - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cancer cells in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a cancer therapy in a subject in need thereof. The invention also discloses methods for preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject. The present invention in addition provides kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods. ## Claims ### Claim 1 A medicament comprising a compound of formula wherein R1 and R2 are independently selected from the group consisting of Na, H, —CH3, —CH2—CH3, —CH2—CH═CH3, n-CH2—CH2—CH3, P(O)(O—CH2—CH3)2, P(O)(OH)2 or P(O)(ONa)2 and wherein R1, R2, R3, R4 and R5 are not H simultaneously, wherein R1 is not —CH3 when R2 is P(O)(ONa)2 or P(O)(OH)2 and each of R3, R4 and R5 is H, and wherein R1 is not —CH3 or H when R2 is —CH3 and each of R3, R4 and R5 is H; and wherein R3, R4 and R5 are independently selected from the group consisting of H, CH3, —CH2—CH3, —CH2—CH═CH3, and CnH2n+1 with n=3−10. ### Claim 2 (depends on 1) The medicament according to claim 1, wherein the compound is ### Claim 3 (depends on 1) A method for treating melanoma, sarcoma or lung cancer in a subject in need thereof, wherein the method comprises a step of administering an effective amount of a compound according to claim 1 to the subject. ### Claim 4 (depends on 3) The method according to claim 3, wherein the compound is administered to the subject in combination with an effective amount of at least one distinct anticancer agent, and/or the method further comprises a step of exposing the subject to radiotherapy. ### Claim 5 (depends on 3) The method according to claim 3, wherein the subject has melanoma. ### Claim 6 (depends on 3) The method according to claim 3, wherein the subject has lung cancer. ### Claim 7 (depends on 4) The method according to claim 4, wherein the at least one distinct anticancer agent is selected from the group consisting of a chemotherapeutic agent, an immune checkpoint blocker and an anti-cancer vaccine. ### Claim 8 (depends on 3) The method according to claim 3, wherein the method stimulates an anti-cancer immune response in the subject. ### Claim 9 (depends on 3) The method according to claim 3, wherein the subject is a mammal. ### Claim 10 (depends on 9) The method according to claim 9, wherein the subject is a human being. ### Claim 11 (depends on 3) The method according to claim 3, wherein the compound is ### Claim 12 (depends on 1) A composition comprising a compound of formula (I) as described in claim 1 and a pharmaceutically acceptable carrier. ### Claim 13 (depends on 12) The composition according to claim 12, wherein the composition further comprises at least one distinct anticancer agent to be used simultaneously, separately or sequentially. ### Claim 14 (depends on 12) The composition according to claim 12, wherein the compound is ### Claim 15 (depends on 1) A method for inducing or increasing the presentation of Pioneer Translation Products (PTPs)-derived antigens by cancer cells in a subject, wherein the method comprises a step of administering the subject with an effective amount of a compound as described in claim 1. ### Claim 16 (depends on 15) The method according to claim 15, wherein the subject is a mammal. ### Claim 17 (depends on 16) The method according to claim 16, wherein the subject is a human being. ### Claim 18 (depends on 15) The method according to claim 15, wherein the compound is ### Claim 19 (depends on 1) A kit comprising the compound of formula (I) as described in claim 1, and at least one distinct anticancer agent in distinct containers. ### Claim 20 (depends on 3) The method according to claim 3, wherein the subject has a sarcoma. ### Claim 21 (depends on 6) The method according to claim 6 wherein lung cancer is non-small cell lung cancer. ### Claim 22 (depends on 6) The method according to claim 6 wherein lung cancer is small-cell lung cancer.